lxr agonist

27-Hydroxycholesterol (25(R)-27-hydroxy Cholesterol) 是一种有效的、选择性的雌激素受体调节剂和肝X 受体激动剂。

LXR (Liver X receptor) agonist 1 是 LXR 的有效激动剂，能够作用于 LXR-α (AC50: 1.5 nM) 和 LXR-β (AC50: 12 nM)。LXR agonist 1 对动脉粥样硬化表现出研究潜力。

LXR agonist 2 是 LXR (肝 X 受体) 的有效激动剂。LXR agonist 2 能够稳定 NCOA1 (助激活剂)，进而激动 LXR。

LXRβ agonist-2 is a highly potent and β-selective liver X receptor (LXRβ) agonist with EC50 of 7 nM.

LXRβ agonist-3 是一种强效的、选择性的 LXRβ (肝 X 受体 β) 激动剂 (EC50: 0.095 μM)。LXRβ agonist-3 可以有效抑制 U87EGFRvIII 细胞 (IC50: 3.75 μM)。LXRβ agonist-3 表现出抗肿瘤作用，能够抑制恶性胶质瘤。

GW3965 hydrochloride (GW3965 HCl) 是一种肝 X 受体 (LXR) 激动剂，主要作用于 hLXRα (EC50:190 nM) 和 hLXRβ (EC50:30 nM)

GW6340 是一种选择性 LXR 激动剂，具有潜在的抗癌活性，可促进巨噬细胞反向胆固醇转运 (mRCT)，可用于研究动脉粥样硬化。

SR9243 是一种 liver-X-receptor 的反向激动剂，可诱导 LXR-辅阻遏物相互作用。

GW3965 是选择性的肝 X 受体 (LXR) 激动剂，对 hLXRα 和 hLXRβ 的 EC50分别为 190 nM 和 30 nM。

T0901317 是一种口服有效且高度选择性的LXR 激动剂，对 LXRα 的EC50为 20 nM。它激活FXR，EC50为 5 μM。它是RORα和RORγ双重反向激动剂，Ki 值分别为 132 nM 和 51 nM。它诱导细胞凋亡，并抑制低密度脂蛋白受体缺失小鼠动脉粥样硬化的发展。

BE1218 是一种肝 X 受体 (LXR) 反向激动剂，对 LXRα 和 LXRβ有活性，IC50 分别为 9 nM 和 7 nM。

GAC0003A4 是一种有效的 LXR 反向激动剂，具有抗肿瘤活性，能抑制 LXR 蛋白的转录。GAC0003A4 可降解 LXRβ 蛋白，以剂量依赖性方式抑制PDAC细胞增殖。GAC0003A4 有用于研究晚期胰腺癌和其他顽固性恶性肿瘤。

Nagilactone B is extracted from the root bark of Podocarpus nagi and it also is a liver X receptor (LXR) agonist.

SR9238 是有效的肝 X 受体(LXR)反向激动剂，对LXRα和LXRβ的IC50分别为 214 nM 和 43 nM。

24(S)-hydroxy Cholesterol (24S-OHC) 是神经组织中胆固醇消除途径的过表达终末产物，是 LXR 激动剂和选择性 NMDARs 阳性变构调节剂，可作为作为 NPD 生物标志物，诱导小鼠认知能力下降，可用于研究神经系统疾病。

SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019). SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity. References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019).

22(S)-hydroxy Cholesterol is a synthetic oxysterol and a modulator of the liver X receptor (LXR). [1] t prevents monocyte chemoattractant protein 1 (MCP-1) expression induced by the LXR agonist GW 3965 in primary hepatocytes and downregulates mRNA expression of the LXR target genes CD36, ACSL1, and SCD-1 in human myotubes. It decreases triacylglycerol and diacylglycerol synthesis from labeled palmitate and acetate, respectively, in human myoblasts by 50% when used at a concentration of 10 uM. 22(S)-hydroxy Cholesterol also reduces fatty acid synthase (FAS) reporter activity through an LXR response element in the promoter region in COS-1 cells transfected with RXRα and LXRα and decreases the expression of MCP-1 and CCR2 in a mouse model of chronic ethanol consumption.[1] [2] Dietary supplementation of 22(S)-hydroxy cholesterol (30 mg kg per day) leads to less body weight gain and lower liver triacylglycerol levels in rats when fed either a regular chow or high-fat diet as well as prevents an increase in plasma triacylglycerol levels resulting from a high-fat diet.[3]

BMS-779788 (XL-652) 是一种 LXR 的部分激动剂，能够作用于 LXRα (IC50:68 μM) 和 LXRβ (IC50:14 μM)。

DMHCA 是一种选择性 LXR 激动剂，具有抗炎活性，可诱导 ABCA1 表达，上调 FASN 和 SREBP-1alpha 基因的表达。

RGX-104 hydrochloride (SB742881) 是小分子LXR 激动剂，利用 ApoE 基因的转录激活，调节先天免疫。

AZ876 是高亲和力的 LXR 激动剂。它在人的 (h)LXRα 和 hLXRβ 比 GW3965 要分别强 25 和 2.5 倍。

LXR antagonist 2 (compound 10rr) 是一种有效的 LXR (肝 X 受体) 反向激动剂，能够作用于 LXRβ (IC50: 0.36 μM) 和 LXRα (IC50: 2.25 μM)。 LXR antagonist 2 是一种脂肪生成抑制剂，能够下调 LXR 靶基因 SREBP-1c、ACC、FAS 和 SCD-1。LXR antagonist 2 对 Triton WR-1339 诱导的高脂血症小鼠表现出降脂活性。

AZ-1 is an inducer of ABCA1 and apoE. It enhances ABCA1 activity and decreases P2X7 receptor activity. AZ-1 activates endogenous LXR signaling but shows no direct LXRα or LXRβ agonist activity.

AZ-2 is an inducer of ABCA1 and apoE. It enhances ABCA1 activity and decreases P2X7 receptor activity. AZ-2 activates endogenous LXR signaling but shows no direct LXRα or LXRβ agonist activity.